Celebrating the complete acquisition of ownership from GC Green Cross
Last year, prescriptions increased by 2.4 billion won to 16.2 billion won, recording growth.
Daewon Pharmaceutical announced on the 11th that it held the ‘Shinbaro 2025 Kick-Off Meeting’ to commemorate the new beginning of ‘Shinbaro Tablet’, an osteoarthritis treatment drug, at Sebitseom Floating Island in Seocho-gu, Seoul. This event was held to commemorate the recent complete acquisition of Shinbaro’s ownership from GC Green Cross and to pledge successful growth, and it is said that about 500 executives and employees attended.
The event was held with executives and employees gathering and interacting, presenting the background of Shinbaro’s introduction and future vision, awarding awards to outstanding salespeople, and answering questions.
President Baek In-hwan said, “We have a strong determination to grow Shinbaro as Daewon Pharmaceutical’s second new drug. “We will strive to establish it as Daewon Pharmaceutical’s representative product,” he said. Joo-il Kim, vice president of R&D, also said, “We will not spare any effort in active research and investment to improve Shinbaro. “By adjusting the tablet size and changing the formulation, we plan to improve the current dosage of 2 tablets at a time to 1 tablet at a time, and also add new indications and develop combination drugs,” he added.
Shinbaro is Korea’s fourth natural new drug, and is used to treat anti-inflammatory, pain-relieving and osteoarthritis, and is known to have few side effects even when administered long-term. It has grown steadily through co-promotion (two or more companies jointly sell a specific product) with GC Green Cross, and last year, the amount of prescriptions recorded KRW 16.2 billion, an increase of KRW 2.4 billion from the previous year.
Kim Sang-jun, Donga.com reporter ksj@donga.com
rnrn